menu
    • menu
    [{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"PPD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"ETC-159","moa":"Protein-serine O-palmitoleoyltransferase porcupine (PORCN)","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Experimental Drug Development Centre \/ PPD","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ PPD"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EBC-129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Experimental Drug Development Centre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Undisclosed"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EBC-129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Experimental Drug Development Centre \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Undisclosed"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"EBC-129","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Experimental Drug Development Centre \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Parexel"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"Chiltern International","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ETC-1907206","moa":"WEE1","graph1":"Oncology","graph2":"Phase I","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Experimental Drug Development Centre \/ Chiltern International","highestDevelopmentStatusID":"6","companyTruncated":"Experimental Drug Development Centre \/ Chiltern International"},{"orgOrder":0,"company":"Experimental Drug Development Centre","sponsor":"ImmunoScape","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Experimental Drug Development Centre","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Experimental Drug Development Centre \/ Experimental Drug Development Centre","highestDevelopmentStatusID":"3","companyTruncated":"Experimental Drug Development Centre \/ Experimental Drug Development Centre"}]

    Find Clinical Drug Pipeline Developments & Deals by Experimental Drug Development Centre

    Menu

    Experimental Drug Development Centre

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EDDC Granted FDA Fast Track for ADC EBC-129 to Treat Pancreatic Adenocarcinoma

                            Details : EBC-129 is a first-in-class ADC targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6 for treating pancreatic ductal carcinoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 28, 2025

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : ImmunoScape

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-...

                            Details : Through the partnership, EDDC will apply its expertise in therapeutic protein design and antibody engineering to develop these novel TCR-based bispecific molecules for the treatments for solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 21, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : ImmunoScape

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            WuXi XDC Congratulates EDDC on FDA Clearance of IND Application for First Made-in-Singapore Antibody-Drug Conj...

                            Details : EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) that is entering clinical development. It is able to selectively target cancer cells across a range of solid tumours.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 08, 2023

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of EBC-129 in Advanced Solid Tumours

                            Details : EBC-129 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 27, 2023

                            Lead Product(s) : EBC-129

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETC-1907206

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Chiltern International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

                            Details : ETC-1907206 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Precursor Cell Lymphoblastic Leukemia-Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 30, 2018

                            Lead Product(s) : ETC-1907206

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Chiltern International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Experimental Drug Development Centre

                            Singapore arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ETC-159

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembr...

                            Details : ETC-1922159 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2015

                            Lead Product(s) : ETC-159

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth